PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Carbocisteine - Reduction of sputum viscosity
PAD Profile : Carbocisteine - Reduction of sputum viscosity
Keywords :
mucolytics, excessive mucous production, COPD, Bronchiectasis
Brand Names Include :
Mucodyne
Traffic Light Status
Status 1 of 3.
Status :
Green (see narrative)
Important
Preferred
Formulations :
- Capsules
Important Information :
Do not use in patients with active peptic ulcer disease or risk of GI bleeding.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 3.
Status :
Green (see narrative)
Important
Formulations :
- Sachets (oral solution)
Important Information :
Reserve for patients with swallowing difficulties (aged 15 years and over)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 3 of 3.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
03 April 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Area Prescribing Committee approved the Primary Care guidance for prescribing oral mucolytics to reduce sputum viscosity.
Carbocisteine should be prescribed generically.
Refer to the guidance for full details of product choice in adults, children and patients with swallowing difficulties.
03 May 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
GENERIC Carbocisteine has been considered by the PCN and has been assigned a GREEN traffic light status.
NOTE - the branded product, Mucodyne, was considered BLACK at the PCN in May 2017.
Associated BNF Codes
03. Respiratory System
03.07.00. Mucolytics